Uncategorized

20 May: Life Sciences Ontario calls on federal government to delay and reconsider federal price controls as all Canadians focus on COVID efforts

Canada and Ontario’s life sciences sector has been leading unprecedented efforts to respond to the COVID-19 crisis. However, our sector faces an impending challenge – the planned implementation of the Government of Canada’s amendments to the Patented Medicines Regulations. These new regulations threaten to divert our sector’s attention and resources away from…

21 Jan: New survey data: Federal drug pricing regulations are already stopping what Canadians want:
access to new medicines as soon as possible

In these unprecedented times, access to new medicines and vaccines has never been more important. However, new federal drug pricing regulations changing the Patented Medicine Prices Review Board (PMPRB) are hurting Canadians’ access to new life-saving medicines and vaccines. According to a recent Research Etc. survey of 43 pharmaceutical leaders:…